EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers

Launched by OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER · Jan 16, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of EMLA topical cream in reducing pain for patients with skin cancers, such as melanoma and squamous cell carcinoma, who are receiving a special injection called Technetium 99. This injection is part of a procedure known as lymphoscintigraphy, which helps doctors locate important lymph nodes to check for cancer. While this injection is necessary for the treatment, it can cause some discomfort due to the sensitivity of the skin. The EMLA cream contains numbing ingredients that may help lessen this pain, and this is the first time it’s being tested specifically for this type of procedure in skin cancer patients.

To be eligible for the trial, participants must be between 18 and 99 years old and have a confirmed diagnosis of certain skin cancers that require this lymph node mapping procedure. However, those with allergies to the cream or specific health conditions that could complicate the procedure won't be able to participate. If you join the trial, you can expect to use the cream before the injection, and the goal is to see if it makes the experience more comfortable. This study could contribute valuable information about managing pain during essential cancer treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Biologic males or females
• • 18 - 99 years of age
• • Histologically confirmed cutaneous melanoma, Merkel cell carcinoma, squamous cell carcinoma, or other cutaneous malignancy for which lymphoscintigraphy and sentinel lymph node biopsy has been recommended.
• Exclusion Criteria:
• • Known allergy or intolerance to EMLA cream, lidocaine, prilocaine, or any other local anesthetic
• • History of adhesive allergy
• • Contraindication to Tc99 injection for sentinel lymph node mapping
• • Incarcerated patients
• • Patients incapable of independently providing consent
• • Mucosal or genital lymphoscintigraphy site
• • Pregnancy
• • Participant self-declared or Ohio State University (OSU) medical chart listing chronic pain as a pre-existing diagnosis
• • Participants with chronic pain as defined by the Centers for Disease Control and Prevention (CDC):"pain lasting 3 months or more that can be caused by a disease or condition, injury, medical treatment, or unknown reason" excluding those with stable co-morbid conditions such as peripheral neuropathy, fibromyalgia, arthritis, and cancer-related pain who do not require narcotics. Patients who require narcotics at any time within the 7-day period leading up to the procedure